1Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial [J]. Lancet, 2006,368 (9541) : 1096-1105. DOI: 10. 1016/ S0140-6736 (06) 69420-8.
2Scirlca BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus [J]. N Engl J Med, 2013, 369 (14): 1317-1326. DOI: 10. 1056/NEJMoa1307684.
3White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes [ J ]. N Engl J Med, 2013, 369 ( 14 ) : 1327-1335. DOI: 10. 1056/ NEJMoa1305889.
4Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes [ J ] . N Engl J Med, 2015,373(3) :232-242. DOI: 10. 1056/NE.IMoa1501352.
5Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type2 Diabetes[ J]. N Engl J Med, 2015, 373 (22) : 2117-2128. DOI: 10. 1056/ NEJMoa1504720.
6Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes[ J]. N Engl J Med, 2016. [ 2016-06-221. http://www, nejm. org/doi/full/lO. 1056/ NEJMoa1603827. [ published online ahead of print June 13, 20161. DOI: 10. 1056/NEJMoa1603827.
